Back
Helmerich & Payne 10K Form
Sell
45
HP
Helmerich & Payne
Last Price:
33.93
Seasonality Move:
8.25%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-04-24 | 10Q | HP/Helmerich & Payne Quarterly |
2024-01-29 | 10Q | HP/Helmerich & Payne Quarterly |
2023-11-08 | 10K | HP/Helmerich & Payne Annual |
2023-07-26 | 10Q | HP/Helmerich & Payne Quarterly |
2023-04-26 | 10Q | HP/Helmerich & Payne Quarterly |
2023-01-30 | 10Q | HP/Helmerich & Payne Quarterly |
Receive HP News And Ratings
See the #1 stock for the next 7 days that we like better than HP
HP Financial Statistics
Sales & Book Value
Annual Sales: | $2.87B |
---|---|
Cash Flow: | $63.01M |
Price / Cash Flow: | 15.74 |
Annual Sales: | $28.93 |
Price / Book: | 1.25 |
Profitability
EPS (TTM): | 3.43000 |
---|---|
Net Income (TTM): | $346.31M |
Gross Margin: | $775.01M |
Return on Equity: | 12.46% |
Return on Assets: | 7.85% |
Helmerich & Payne Earnings Forecast
Key Helmerich & Payne Financial Ratios
- The Gross Profit Margin over the past 40 years for HP is 26.98%.
- The Selling, General & Administrative Expenses for HP have been equal to 7.19% of Gross Profit Margin.
- The Research & Development expenses have been 1.05% of Revenue.
- The Interest Expense is 3.98% of Operating Income.
- The Net Earning history of HP is 15.11% of Total Revenues.
- Per Share Earnings over the last 40 years have been positive in 20 years.
Helmerich & Payne Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | S&P500 |
---|---|
Industry: | Energy Equipment & Services |
Sector: | Energy |
Current Symbol: | HP |
CUSIP: | 423452 |
Website: | helmerichpayne.com |
Debt
Debt-to-Equity Ratio: | 0.19 |
---|---|
Current Ratio: | 2.12 |
Quick Ratio: | 1.54 |
Price-to-Earnings
Trailing P/E Ratio: | 8.68 |
---|---|
Forward P/E Ratio: | 9.85 |
HP Technical Analysis vs Fundamental Analysis
Sell
45
Helmerich & Payne (HP)
is a Sell
Is Helmerich & Payne a Buy or a Sell?
-
Helmerich & Payne stock is rated a Sell
The current Helmerich & Payne [HP] share price is $36.20. The Score for HP is 45, which is 10% below its historic median score of 50, and infers higher risk than normal.